Journal: Purinergic Signalling

Article Title: Characterization of purinergic receptor expression in ARPKD cystic epithelia

doi: 10.1007/s11302-018-9632-5

Figure Lengend Snippet: Calcium transient in the cystic monolayer in response to P2X receptor agonist αβmeATP. a Representative changes of the cystic cells’ intracellular calcium levels in response to various concentrations of α,β-methylene-ATP (αβmeATP). Shown are representative transients from different cysts (12÷15 cells/ROIs were analyzed per each transient). b Response to ATP in a cystic monolayer is sustained after application of αβmeATP with 15-min-long washouts between applications of the compounds. N = 4 rats per group, 5÷8 cystic monolayers were tested in each group. c Summary for the amplitude and total [Ca2+]i production (AUC) for ATP and αβmeATP (200 μM each) (N ≥ 3 cyst monolayers for each group at selected concentration of agonist)

Article Snippet: P2 receptor modulating compounds were obtained from Tocris/Bio-Techne (Minneapolis, MN): α,β-meATP (no. 3209), 5-BDBD (no. 3579), NF 449 (no. 1391), AZ10606120 (no. 3323), and isoPPADS (no. 0683) and diluted according to manufacturer’s guidelines. table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Target receptor IC 50 /EC 50 Applied concentrations P2 Receptors Agonists αβmeATP Most P2X (P2X 4 in high concentrations) > 100 μM for P2X 4 ; 0.5 μM for other P2X 50–400 μM P2 Receptors Antagonists 5-BDBD P2X 4 0.50 μM 10 μM NF 449 P2X 1 /P2X 1/5 /P2X 2/3 /P2X 3 /P2X 2 /P2X 4 0.28 nM/0.69 nM/120 nM/1820 nM/47 μM/300 μM 40 μM AZ10606120 P2X 7 20 nM 10 μM isoPPADS non-selective P2X antagonist, affects P2Y (>IC 50 ~ 0.9 mM) 1–2.6 μM 20 μM Open in a separate window P2 receptor pharmacology used Western blotting Kidney cortical lysates were prepared as previously described [ 34 ].

Techniques: Concentration Assay